PAXLOVID

(nirmatrelvir tablets; ritonavir tablets)

Find PAXLOVID medical information:

Find PAXLOVID medical information::

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PAXLOVID Quick Finder

The PAXLOVID Product Monograph is available here

PAXLOVID (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID is not authorized:

For initiation of treatment in patients requiring hospitalization due to severe or critical COVID19.
For pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
For use for longer than 5 consecutive days.

Resources

Didn’t find what you were looking for?

Contact us

Call 1-800-463-6001*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:

Canada Vigilance Program

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.